Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.79 |
| ▸ | AKT2 | P31751 | 14/20 | 0.77 |
| ▸ | AKT3 | Q9Y243 | 14/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31455787 | 0.96 | AKT1 (0.73) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL2177098 | 0.96 | AKT1 (0.75) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL2173016 | 0.95 | AKT1 (0.78) | AKT1AKT2AKT3CYP2C9CYP3A4 | |
| SCHEMBL2173954 | 0.94 | AKT1 (0.78) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL31455680 | 0.93 | AKT1 (0.69) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL31455602 | 0.93 | AKT1 (0.68) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL31455630 | 0.90 | AKT1 (0.65) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL31455989 | 0.90 | AKT1 (0.68) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL2177066 | 0.89 | AKT1 (1.00) | AKT1AKT2AKT3 | |
| SCHEMBL31455920 | 0.88 | AKT1 (0.66) | AKT1AKT2AKT3CYP2C9CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2519522-B1 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE INC (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2519522-B1 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE INC (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8501770-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501770-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501770-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2519522-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ArQule, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2011082270-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE. INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011082270-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE. INC. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | AKT1 2285/4885AKT2 1216/4885AKT3 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.